Articles & Issues

Alert me when new Journal Issues are available via Email Alert   Request TOC Alert via email or RSS Feed   Request RSS feed of TOC

Decade: 2010-2019

Year: 2012

Issue: Vol 48 | No. 3 | February 2012 | Pages 289-408

Cover Image

Search Within This Issue

16 Articles:

  • 1
Drug development
Article Title Author(s) Pages
A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: An Innovative Therapies for Children with Cancer (ITCC) study

28 November 2011

Birgit Geoerger, Edward J. Estlin, Isabelle Aerts, Pamela Kearns, Brenda Gibson, Nadège Corradini, François Doz, Pilar Lardelli, Bernardo De Miguel, Arturo Soto, Raquel Prados, Gilles Vassal et al. 289-296
Breast cancer
Article Title Author(s) Pages
Physical activity in a German breast cancer patient cohort: One-year trends and characteristics associated with change in activity level

19 September 2011

Christina Huy, Martina E. Schmidt, Alina Vrieling, Jenny Chang-Claude, Karen Steindorf et al. 297-304
Tetraploidy in BRCA2 breast tumours

02 December 2011

Asta Bjork Jonsdottir, Olafur Andri Stefansson, Johannes Bjornsson, Jon G. Jonasson, Helga M. Ogmundsdottir, Jorunn E. Eyfjord et al. 305-310
Urologic oncology
Article Title Author(s) Pages
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial

20 June 2011

D. Cella, A.S. Pickard, M.S. Duh, A. Guerin, N. Mishagina, L. Antràs, M.P. Neary, L. McCann, R. Hodge, C.N. Sternberg et al. 311-323
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

01 August 2011

Viktor Grünwald, Pierre I. Karakiewicz, Sevil E. Bavbek, Kurt Miller, Jean-Pascal Machiels, Se-Hoon Lee, James Larkin, Petri Bono, Sun Young Rha, Daniel Castellano, Christian U. Blank, Jennifer J. Knox, Robert Hawkins, Oezlem Anak, Marianne Rosamilia, Jocelyn Booth, Nicoletta Pirotta, István Bodrogi, on behalf of the REACT Study Group et al. 324-332
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

03 January 2012

E. Calvo, B. Escudier, R.J. Motzer, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, V. Grünwald, J.A. Thompson, A. Ravaud, D. Kim, A. Panneerselvam, O. Anak, R.A. Figlin et al. 333-339
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis

29 December 2011

Cristina Gomez-Fernandez, Benjamin C. Garden, Shenwong Wu, Darren R. Feldman, Mario E. Lacouture et al. 340-346
Melanoma
Article Title Author(s) Pages
Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: A national multicentre study

24 October 2011

Rikke Riber-Hansen, Nina Hastrup, Ole Clemmensen, Nille Behrendt, Siri Klausen, Mette Ramsing, Eva Spaun, Stephen Jacques Hamilton-Dutoit, Torben Steiniche et al. 347-352
Neuro-oncology
Article Title Author(s) Pages
Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience

24 October 2011

L. Lafay-Cousin, C. Hawkins, A.S. Carret, D. Johnston, S. Zelcer, B. Wilson, N. Jabado, K. Scheinemann, D. Eisenstat, C. Fryer, A. Fleming, C. Mpofu, V. Larouche, D. Strother, E. Bouffet, A. Huang et al. 353-359
Leukemia
Article Title Author(s) Pages
The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the EWALL

26 December 2011

Sebastian Giebel, Xavier Thomas, Helene Hallbook, Klaus Geissler, Jean-Michel Boiron, Francoise Huguet, Elisabeth Koller, Ulrich Jaeger, Bengt Smedmyr, Andrzej Hellmann, Jerzy Holowiecki et al. 360-367
Quality of life
Article Title Author(s) Pages
Evolution of requests to hasten death among patients managed by palliative care teams in France: A multicentre cross-sectional survey (DemandE)

31 October 2011

Edouard Ferrand, Jean-François Dreyfus, Mélanie Chastrusse, Françoise Ellien, François Lemaire, Marc Fischler et al. 368-376
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)

17 November 2011

Gianfranco A. Pesce, Dirk Klingbiel, Karin Ribi, Abderahim Zouhair, Roger von Moos, Marc Schlaeppi, Clemens B. Caspar, Natalie Fischer, Sandro Anchisi, Solange Peters, Richard Cathomas, Jürg Bernhard, Nina M. Kotrubczik, Giannicola D’Addario, Christiane Pilop, Damien C. Weber, Stephan Bodis, Miklos Pless, Michael Mayer, Roger Stupp et al. 377-384
Clinical trial design
Article Title Author(s) Pages
Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?

24 November 2011

Eitan Amir, Bostjan Seruga, Ryan Kwong, Ian F. Tannock, Alberto Ocaña et al. 385-388
Basic and preclinical research
Article Title Author(s) Pages
Targeting Raf/MEK/ERK pathway in pituitary adenomas

28 November 2011

Zhang Suojun, Wan Feng, Guo Dongsheng, Lei Ting 389-395
The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy

09 December 2011

Emma Hernlund, Maria Hägg Olofsson, Walid Fayad, Mårten Fryknäs, Karolina Lesiak-Mieczkowska, Xiaonan Zhang, Slavica Brnjic, Vivien Schmidt, Padraig D’Arcy, Tobias Sjöblom, Angelo De Milito, Rolf Larsson, Stig Linder et al. 396-406
Corrigendum
Article Title Author(s) Pages
Corrigendum to “Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis” [Eur J Cancer 47 (12) (2011) 1826–1836]

29 December 2011

Stephen J. Clarke, Sonia Yip, Chris Brown, Guy A. van Hazel, David T. Ransom, David Goldstein, G. Mark Jeffrey, Niall C. Tebbutt, Martin Buck, Raymond M. Lowenthal, Amy Boland, Val Gebski, John Zalcberg, R. John Simes, on behalf of the Australasian Gastro-Intestinal Trials Group et al. 407
free full text
  • 1